Nasdaq Halts Theravance Ahead of FDA Panel Meeting on COPD Drug – Fox Business
 Headlines & Global News |
Nasdaq Halts Theravance Ahead of FDA Panel Meeting on COPD Drug
Fox Business Theravance Inc. (THRX) said Nasdaq halted trading in its stock ahead of U.S. regulators' scheduled review of the new drug application for Breo Ellipta, a once-daily inhaled drug designed to treat chronic obstructive pulmonary disease, or COPD. Theravance Inc. (THRX) Has Broken Out To A 5-Month High – NASDAQ.com |
